Complete Blood Count-Derived Biomarkers’ Association with Risk of PD-1 or PD-1/CTLA-4 Inhibitor-Induced Hypothyroidism in Patients with Solid Tumors
Background: A novel and highly effective strategy for tumor immunotherapy involves enhancing host immune responses against tumors through the blockade of checkpoint molecules. The most common toxicities associated with checkpoint blockade therapies include autoimmune damage to various organs. Purpos...
Saved in:
Main Authors: | Ketevan Lomidze, Nino Kikodze, Marine Gordeladze, Nino Charkviani, Tinatin Chikovani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Immuno |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-5601/5/2/21 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01) -
Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01) -
The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024-07-01) -
CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01) -
Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
by: Shintaro Iwama, et al.
Published: (2025-06-01)